"It seems to me that treating patients with the midkine protein has potential in some indications, whereas inhibiting it is a strategy for other indications."
This is the simple distinction between Lyramid and Kinera, MP.
The Lyramid programs are based upon the treatment of diseases by inhibiting the midkine protein, with an antibody serving as the therapeutic agent. For the Kinera programs the protein functions as the therapeutic agent.
Midkine Study: Important Role in Pediatric Heart Failure, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
